Achromatopsia - Pipeline Review, H1 2016

  • ID: 3759003
  • Report
  • 40 pages
  • Global Markets Direct
1 of 5
Achromatopsia - Pipeline Review, H1 2016

Summary

‘Achromatopsia - Pipeline Review, H1 2016’, provides an overview of the Achromatopsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Achromatopsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Achromatopsia and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Achromatopsia
- The report reviews pipeline therapeutics for Achromatopsia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Achromatopsia therapeutics and enlists all their major and minor projects
- The report assesses Achromatopsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Achromatopsia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Achromatopsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Achromatopsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Achromatopsia Overview

Therapeutics Development

Pipeline Products for Achromatopsia - Overview

Achromatopsia - Therapeutics under Development by Companies

Achromatopsia - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Achromatopsia - Products under Development by Companies

Achromatopsia - Companies Involved in Therapeutics Development

Amgen Inc.

Applied Genetic Technologies Corporation

Achromatopsia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Gene Therapy for Achromatopsia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gene Therapy for X-linked retinoschisis and Achromatopsia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gene Therapy to Activate CNGA3 for Achromatopsia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gene Therapy to Activate CNGB3 for Achromatopsia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gene Therapy to Activate Cone Photoreceptor cGMP-Gated Channel for Achromatopsia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NT-501 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Achromatopsia - Recent Pipeline Updates

Achromatopsia - Product Development Milestones

Featured News & Press Releases

Apr 20, 2016: AGTC Announces Publication of Safety and Biodistribution Data Supporting Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia

Jan 07, 2016: AGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases

Nov 23, 2015: AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat Achromatopsia

Nov 02, 2015: AGTC Files Investigational New Drug Application for the Treatment of Achromatopsia Caused by Mutations in the CNGB3 Gene

Oct 22, 2015: AGTC Announces Orphan Drug Designation in the European Union for Gene Therapy to Treat Achromatopsia

Aug 27, 2015: AGTC Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration

May 18, 2015: AGTC Announces New Data Supporting Novel Gene-Based Therapies for Rare Inherited Retinal Diseases

May 04, 2015: Novel Gene-Based Therapy for Achromatopsia Demonstrates Functional Rescue of Cone Cells

Jul 23, 2013: The University of Florida and AGTC Secure $8.4M Grant to Study Rare Eye Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Achromatopsia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Achromatopsia - Pipeline by Amgen Inc., H1 2016

Achromatopsia - Pipeline by Applied Genetic Technologies Corporation, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Achromatopsia Therapeutics - Recent Pipeline Updates, H1 2016

List of Figures

Number of Products under Development for Achromatopsia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Amgen Inc.
Applied Genetic Technologies Corporation
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll